2 Abstract
Widespread access to over-the-counter at-home COVID-19 tests was a crucial component of the United States’ public health response to the COVID-19 pandemic. For at-home testing to be effective, it is essential for the tests to be not only available but also usable and accessible to people with disabilities. In the present study, a survey was conducted to collect feedback about people’s experiences using over-the-counter COVID-19 tests, with an aim to identify barriers to the accessibility of COVID-19 tests for people with disabilities. Survey respondents self-identified as having little to no vision, low vision, or limited dexterity. The survey covered ten at-home COVID-19 test brands. For each test that a respondent had used, the survey included questions about whether the user was able to complete the test independently or whether they needed assistance, the ease of use for performing each part of the testing procedure, and any difficulties that the user encountered while using the test. The survey also included questions for each test regarding the use of mobile applications, digital instructions, and customer service. This report presents the results of nearly 400 responses to the accessibility survey. The results offer an improved understanding of accessibility barriers for at-home COVID-19 tests; designers of at-home diagnostic tests can apply this knowledge in order to improve the accessibility of over-the-counter COVID-19 tests and other at-home diagnostic tests to people with disabilities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by NIH grants U54 EB027690 02S1 and U54 EB027690 05S1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Office of Research Integrity Assurance of Georgia Institute of Technology waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
